Journal article
Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
Abstract
Safe and effective vaccines are needed to end the COVID-19 pandemic. Here, we report the preclinical development of a lipid nanoparticle–formulated SARS-CoV-2 mRNA vaccine, PTX-COVID19-B. PTX-COVID19-B was chosen among three candidates after the initial mouse vaccination results showed that it elicited the strongest neutralizing antibody response against SARS-CoV-2. Further tests in mice and hamsters indicated that PTX-COVID19-B induced robust …
Authors
Liu J; Budylowski P; Samson R; Griffin BD; Babuadze G; Rathod B; Colwill K; Abioye JA; Schwartz JA; Law R
Journal
Science Advances, Vol. 8, No. 3,
Publisher
American Association for the Advancement of Science (AAAS)
Publication Date
January 21, 2022
DOI
10.1126/sciadv.abj9815
ISSN
2375-2548
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AnimalsAntibodies, NeutralizingAntibodies, ViralCD4 Lymphocyte CountCD8-Positive T-LymphocytesCOVID-19COVID-19 VaccinesCanadaCell LineCricetinaeDrug Evaluation, PreclinicalFemaleHEK293 CellsHumansImmunity, CellularImmunity, HumoralLiposomesMaleMiceMice, Inbred BALB CMice, Inbred C57BLNanoparticlesSARS-CoV-2Spike Glycoprotein, CoronavirusTh1 CellsVaccines, SyntheticmRNA Vaccines